• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-CDKN2A antibody :: Goat CDKN2A/p16INK4a Polyclonal Antibody

Scan QR to view Datasheet
Catalog # MBS421217
Unit / Price
Scan QR to view Datasheet
  0.1 mg  /  $300 +1 FREE 8GB USB
Western Blot (WB)
Product Name

CDKN2A/p16INK4a, Polyclonal Antibody

Full Product Name

Goat anti-CDKN2A (isoform 1)/p16INK4a Antibody

Product Synonym Names
Goat Anti-CDKN2A (isoform 3) Antibody; CDKN2A; p16INK4a; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); HGNC: 1787; ARF; CDK4I; CDKN2; CMM2; INK4; INK4a; MLM; MTS1; TP16; p14; p14ARF; p16; p16INK4; p19; CDK4 inhibitor p16-INK4; cell cycle negative regulator beta; cyclin-; CDKN2A antibody; p16INK4a antibody; cyclin-dependent kinase inhibitor 2A (melanoma; p16; inhibits CDK4) antibody; HGNC: 1787 antibody; ARF antibody; CDK4I antibody; CDKN2 antibody; CMM2 antibody; INK4 antibody; INK4a antibody; MLM antibody; MTS1 antibody; TP16 antibody; p14 antibody; p14ARF antibody; p16 antibody; p16INK4 antibody; p19 antibody; CDK4 inhibitor p16-INK4 antibody; cell cycle negative regulator beta antibody; cyclin- antibody; CDKN2A (isoform 1) / p16INK4a
Product Synonym Gene Name
Antibody/Peptide Pairs
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Immunogen Sequence
HARIDAAEGP SDIPD
OMIM
151623
Clonality
Polyclonal
Host
Goat
Species Reactivity
Tested: Human; Expected from sequence similarity: Human
Purity/Purification
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Form/Format
Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Concentration
100ug specific antibody in 200ul (lot specific)
Immunogen
Peptide with sequence C-HARIDAAEGPSDIPD, from the C Terminus of the protein sequence according to NP_000068.1; NP_001182061.1.
Epitope
C Terminus
Note
This antibody is expected to recognise isoform p16INK4a (NP_000068.1) and isoform p16gamma (NP_001182061.1).
Preparation and Storage
Aliquot and store at -20 degree C. Minimize freezing and thawing.
ISO Certification
Manufactured in an ISO 9001:2008 Certified Laboratory.
Other Notes
Small volumes of anti-CDKN2A antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for anti-CDKN2A antibody
Peptide ELISA (EIA), Western Blot (WB)
Application Notes for anti-CDKN2A antibody
Peptide ELISA: Antibody detection limit dilution 1: 32000.
Western Blot: Approx.16-18kDa band observed in lysates of the cell lines A431 and HeLa (calculated MW of 16.5kDa according to NP_000068.1). Recommended concentration: 0.1-1ug/ml.

Western Blot (WB) of anti-CDKN2A antibody
(1ug/ml) staining of HeLa Lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
anti-CDKN2A antibody Western Blot (WB) (WB) image
NCBI/Uniprot data below describe general gene information for CDKN2A. It may not necessarily be applicable to this product.
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI Related Accession #
Manufactured in an ISO 9001:2008 Certified Laboratory.NP_001182061.1[Other Products]
NCBI GenBank Nucleotide #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
8,731 Da
NCBI Official Full Name
cyclin-dependent kinase inhibitor 2A isoform p16INK4a
NCBI Official Synonym Full Names
cyclin-dependent kinase inhibitor 2A
NCBI Official Symbol
CDKN2A  [Similar Products]
NCBI Official Synonym Symbols
ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A
  [Similar Products]
NCBI Protein Information
cyclin-dependent kinase inhibitor 2A
UniProt Protein Name
Cyclin-dependent kinase inhibitor 2A
UniProt Synonym Protein Names
Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A
UniProt Gene Name
CDKN2A  [Similar Products]
UniProt Synonym Gene Names
CDK4I; MTS-1; p16-INK4; p16INK4A  [Similar Products]
UniProt Entry Name
CDN2A_HUMAN
NCBI Summary for CDKN2A
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
UniProt Comments for CDKN2A
p16-INK4A: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported.

Protein type: Tumor suppressor; Cell cycle regulation; Nucleolus

Chromosomal Location of Human Ortholog: 9p21

Cellular Component: cytoplasm; cytosol; mitochondrion; nuclear body; nucleolus; nucleoplasm; nucleus; protein complex

Molecular Function: cyclin-dependent protein kinase inhibitor activity; DNA binding; NF-kappaB binding; p53 binding; protein binding; protein kinase binding; SUMO ligase activity; transcription factor binding; ubiquitin-protein ligase inhibitor activity

Biological Process: apoptotic mitochondrial changes; caspase activation; cell cycle arrest; G1/S transition of mitotic cell cycle; inhibition of NF-kappaB transcription factor; mitochondrial depolarization; mitochondrion degradation; negative regulation of B cell proliferation; negative regulation of cell growth; negative regulation of cell proliferation; negative regulation of cell-matrix adhesion; negative regulation of cyclin-dependent protein kinase activity; negative regulation of immature T cell proliferation in the thymus; negative regulation of phosphorylation; negative regulation of protein kinase activity; negative regulation of transcription, DNA-dependent; negative regulation of ubiquitin-protein ligase activity; positive regulation of apoptosis; positive regulation of DNA damage response, signal transduction by p53 class mediator; positive regulation of protein sumoylation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; protein destabilization; protein polyubiquitination; protein stabilization; protein sumoylation; Ras protein signal transduction; regulation of G2/M transition of mitotic cell cycle; regulation of protein export from nucleus; regulation of protein stability; rRNA processing; somatic stem cell division; transcription, DNA-dependent

Disease: Melanoma, Cutaneous Malignant, Susceptibility To, 2; Melanoma-astrocytoma Syndrome; Melanoma-pancreatic Cancer Syndrome
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000